...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International journal of antimicrobial agents >Evaluation of a triple-drug combination for treatment of experimental multidrug-resistant pneumococcal meningitis
【24h】

Evaluation of a triple-drug combination for treatment of experimental multidrug-resistant pneumococcal meningitis

机译：三药联合治疗实验性多药耐药肺炎球菌脑膜炎的评价

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To evaluate the therapeutic efficacy of ceftriaxone+vancomycin+rifampicin (CVR) in the treatment of pneumococcal meningitis caused by a multidrug-resistant strain, single-drug regimens (ceftriaxone 100 mg/kg, rifampicin 15 mg/kg, or vancomycin 20 mg/kg), double-drug regimens (ceftriaxone + vancomycin [CV] and ceftriaxone + rifampicin [CR]) and a triple-drug combination (CVR) with or without dexamethasone were compared in a rabbit meningitis model. Meningitis was induced by a highly penicillin-resistant (MIC 2 mg/l) and ceftriaxone-resistant (MIC 4 mg/l) pneumococcal strain. Final therapeutic efficacy was evaluated by the bacterial concentration at 24 h, and the bacterial killing rate was also evaluated. All combination regimens were superior to ceftriaxone or vancomycin single-drug regimens with regard to sterilisation of CSF and bacterial killing rate. Rifampicin was as effective as combination regimens. Regardless of dexamethasone, therapeutic efficacy of CVR and CR were superior to that of CV. CVR showed comparable therapeutic efficacy to CR. Data suggested that CVR would not have additional therapeutic benefit over CR during the initial 24 h of treatment. (C) 2003 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved. [References: 10]
机译：评估头孢曲松+万古霉素+利福平（CVR）在由多药耐药菌株，单药治疗（头孢曲松100 mg / kg，利福平15 mg / kg或万古霉素20 mg /公斤），在兔脑膜炎模型中比较了双重药物治疗方案（头孢曲松+万古霉素[CV]和头孢曲松+利福平[CR]）和含或不含地塞米松的三药联合治疗（CVR）。脑膜炎是由高度耐青霉素（MIC 2 mg / l）和耐头孢曲松（MIC 4 mg / l）肺炎球菌引起的。通过24小时的细菌浓度评估最终的治疗效果，并评估细菌的杀灭率。在脑脊液的灭菌和细菌杀灭率方面，所有联合方案均优于头孢曲松或万古霉素单药方案。利福平与联合用药一样有效。无论地塞米松如何，CVR和CR的疗效均优于CV。 CVR显示出与CR相当的治疗功效。数据表明，在治疗的最初24小时内，CVR不会比CR具有更多的治疗益处。 （C）2003年Elsevier B.V.和国际化学疗法学会。版权所有。 [参考：10]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号